Avecho Biotechnology Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AVE.AX | NTRB | 18H0.F | HRTX | ALGS | IBO | |
|---|---|---|---|---|---|---|
| Market cap | 54.09M | 72.33M | 5.74M | 57.24M | 29.60M | 30.33M |
| P/E (TTM) | — | — | — | — | — | 0.3 |
| Forward P/E | — | -25.9 | — | -2.7 | -0.9 | — |
| Price/book | — | 13.6 | -1.3 | 9.7 | 0.9 | 2.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +133.33% | −23.07% | −43.75% | −74.79% | −50.11% | −48.84% |
| Today | 0.00% | −0.34% | 0.00% | +0.27% | +1.94% | −4.83% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All AVE.AX news ›Avecho Biotechnology Limited (ASX:AVE): Phosphorylated Vitamin E Technology and Oral Drug Delivery
For Avecho Biotechnology Limited (ASX:AVE), the distinction between a technology’s intended function and demonstrated outcomes is important. Product-specific evidence is required before general technical claims can be treated as validated…
From articles in the 4Search news index.